Business, energy, technology, markets and global industry news from Business News Today

hemophilia A

PharmaDeviceNews hemophilia A
Representative image: A healthcare professional prepares a subcutaneous injection in a clinical setting, reflecting the treatment shift highlighted by Pfizer’s Hympavzi EU indication expansion for hemophilia A and hemophilia B patients with inhibitors.
Pharma & Biotech

EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?

Hemophilia care is moving beyond factor replacement. Pfizer’s Hympavzi EU expansion tests how far anti-TFPI therapy can scale.

Read More
Representative image: INOVIO Pharmaceuticals’ upcoming ASCO and ASGCT conference posters place INO-3107 DNA immunotherapy and early hemophilia A gene transfer research under the spotlight as investors watch the biotech firm’s regulatory and platform strategy.
Pharma & Biotech

INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy

INOVIO has a regulatory clock ticking. New INO-3107 and hemophilia A data may show whether its DNA platform can move beyond promise.

Read More
Representative image of subcutaneous injection for hemophilia management, highlighting the type of delivery used in anti-TFPI therapies like HYMPAVZI that may redefine care for patients with inhibitors.
Features & Analysis

Can anti-TFPI drugs like HYMPAVZI reshape the standard of care in inhibitor-positive hemophilia?

Pfizer Inc. has moved a step closer to reshaping the treatment paradigm for one of hemophilia’s most challenging patient subgroups. The company’s investigational therapy HYMPAVZI (marstacimab) demonstrated a 93 percent reduction in bleeding episodes in patients with hemophilia A or B who have developed inhibitors, according to data presented at the 67th American Society of

Read More